Page 214 - Read Online

Page 14 of 16 Landi et al. Neuroimmunol Neuroinflammation 2018;5:29 I http://dx.doi.org/10.20517/2347-8659.2018.35

Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH. Disrupt-
ing the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain
tumors. Sci Transl Med 2017;9:eaaf2968.
63. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-
brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-92.
64. Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer
Res 2013;19:4717-27.
65. Randazzo D, Desjardins A, Chandramohan V, Sampson JH, Peters KB, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D,
Healy P, Lipp ES, Friedman AH, Bigner DD. Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via
convection-enhanced delivery for adult patients with recurrent malignant glioma. J Clin Oncol 2017;35 suppl 15:e13532.
66. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podo-
planin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2013;132:2339-48.
67. Rainov NG, Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-
targeted toxin (NBI-3001). J Neurooncol 2004;66:197-201.
68. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD,
Croteau DJ, Sherman JW, Puri RK. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant
glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44.
69. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S,
McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Wil-
liams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric
protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38)
for the treatment of malignant brain tumors. J Neurooncol 2003;65:27-35.
70. Luther N, Zhou Z, Zanzonico P, Cheung N-K, Humm J, Edgar MA, Souweidane MM. The potential of theragnostic 124I-8H9 convec-
tion-enhanced delivery in diffuse intrinsic pontine glioma. Neuro Oncol 2014;16:800-6.
71. Y-mAbs Therapeutics. Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previ-
ously Treated With External Beam Radiation Therapy. ClinicalTrials.gov Identifier: NCT01502917.
72. Przepiorka D, Ko C-W, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu H-J, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner
S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R. FDA approval: blinatumomab. Clin Cancer Res
2015;21:4035-9.
73. Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy
P, Herndon JE, McLendon RE, Keir ST, Archer GE, Reap E, Sanchez-Perez L, Bigner DD, Sampson JH. A rationally designed fully hu-
man EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clin
Cancer Res 2018; doi: 10.1158/1078-0432.CCR-17-0126.
74. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Ma X, Lu C, Nagahawatte
P, Hedlund E, Rusch M, Pounds S, Lin T, Onar-Thomas A, Huether R, Kriwacki R, Parker M, Gupta P, Becksfort J, Wei L, Mulder HL,
Boggs K, Vadodaria B, Yergeau D, Russell JC, Ochoa K, Fulton RS, Fulton LL, Jones C, Boop FA, Broniscer A, Wetmore C, Gajjar A,
Ding L, Mardis ER, Wilson RK, Taylor MR, Downing JR, Ellison DW, Zhang J, Baker SJ. The genomic landscape of diffuse intrinsic
pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46:444-50.
75. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB,
Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu
H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
76. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid
O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM,
Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med
2012;366:2455-65.
77. Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, Vlahovic G,
Sampson J. OS10.3 Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recur-
rent glioblastoma: CheckMate 143. Neuro Oncol 2017;19:iii21.
78. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
79. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune sys-
tem and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
80. Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin
GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma.
Neuro Oncol 2016;18:195-205.
81. Mahadevan N, Adeni A, Hammerman P, Awad M, Gandhi L, Sholl L. MA15.02 non-synonymous mutation burden in lung carcinoma is
associated with durable clinical response to immune checkpoint blockade. J Thorac Oncol 2017;12:S428-9.
82. Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell
2018;33:581-98.
83. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Brugge-
man C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Genetic basis for clinical response
to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.